查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1787194

全球多种癌症早期检测市场

Multi Cancer Early Detection
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 214 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

到 2030 年，全球多种癌症早期检测市场规模将达到 26 亿美元

全球多重癌症早期检测市场规模预计在2024年为11亿美元，预计到2030年将达到26亿美元，在2024-2030年的分析期内，复合年增长率为15.6%。基因检测面板及液体切片（LDT）是本报告分析的细分市场之一，预计其复合年增长率为13.8%，到分析期结束时将达到14亿美元。液态切片细分市场在分析期间的复合年增长率预计为18.2%。

美国市场规模估计为 2.96 亿美元，中国市场预计复合年增长率为 20.4%

美国多种癌症早期检测市场规模预计在2024年达到2.96亿美元。作为世界第二大经济体，中国预计到2030年市场规模将达到5.568亿美元，在2024-2030年的分析期间内，复合年增长率为20.4%。其他值得关注的区域市场包括日本和加拿大，预计在分析期间内，这两个市场的复合年增长率分别为11.7%和13.9%。在欧洲，预计德国市场的复合年增长率约为12.4%。

全球多种癌症早期检测市场—主要趋势与驱动因素摘要

多种癌症的早期检测如何重塑癌症诊断？

多种癌症早期检测 (MCED) 的出现正在彻底改变癌症检测格局，这是一项突破性的技术，正在彻底改变癌症诊断。与传统的癌症筛检测试（例如乳癌的乳癌X 光检查和结直肠癌的大肠镜检查）不同，这些测试仅针对特定数量的恶性肿瘤，而 MCED 测试利用先进的基因组、表观基因和蛋白质组生物标誌物，可在单次测试中同时检测多种癌症类型。这是透过液态切片来实现的，该液体活检分析血液样本中的循环肿瘤 DNA (ctDNA)、RNA 特征和其他分子变异。癌症仍然是全球最大的死亡原因，因此早期发现对于提高存活率至关重要。根据世界卫生组织 (WHO) 的数据，晚期诊断占癌症相关死亡的很大一部分，凸显了对早期、非侵入性和全面筛检解决方案的迫切需求。随着人工智慧 (AI) 和机器学习 (ML) 演算法增强生物标记识别，MCED 测试现在比以往任何时候都更加准确、扩充性且易于存取。多家生物技术公司和研究机构已透过大规模临床试验检验这些检测方法，并取得了显着进展，证明了在癌症症状出现前识别癌症的潜力。这些方法有望减轻晚期癌症诊断负担，并改善患者预后，这在医学界、投资者和监管机构中引起了前所未有的兴奋。

液态切片和人工智慧将在推进 MCED 方面发挥什么作用？

MCED 技术的核心是液态切片与人工智慧的融合。这两项创新技术显着提高了多重筛检的准确性和效率。传统的组织切片检查虽然有效，但具有侵入性、成本高，并且通常仅限于特定的癌症类型。相较之下，液态生物检体侵入性极小，可以透过识别筛检中的肿瘤衍生基因片段来检测多种癌症。这项技术对于检测难以筛检的癌症尤其有价值，例如胰腺癌、卵巢和食道癌，这些癌症通常直到晚期才被诊断出来。基于人工智慧的模式识别透过快速分析海量遗传、蛋白质组学和代谢标记资料集来区分良性和恶性讯号，进一步增强了 MCED 的功能。基于数百万患者样本训练的人工智慧模型提高了诊断准确性，最大限度地减少了假阳性和假阴性，甚至可以预测检测到的癌症的来源组织。人工智慧在MCED领域的日益普及也促进了持续学习，演算法不断演进，以识别新的癌症亚型并适应新的分子发现。尤其是GRAIL、Guardant Health和Exact Sciences等公司，在人工智慧液态切片活检的商业化方面处于领先地位，其有效性已得到广泛的临床检验。此外，监管机构的核准，例如美国食品药物管理局(FDA)授予领先的MCED检测突破性认证，标誌着我们癌症筛检方式的模式转移。随着这些技术的成熟，它们与常规健康检查的整合有望成为预防医学的新标准，将早期检测转变为一种经济有效的救生策略。

医疗保健政策和市场投资如何加速 MCED 的采用？

政府政策、医疗基础设施和投资趋势在塑造 MCED 市场应用轨迹方面发挥关键作用。随着世界各地的医疗保健系统努力应对晚期癌症治疗的经济负担，人们越来越认同早期检测策略的成本效益。多个国家的医疗保健组织和保险公司正在探索 MCED 检测的报销模式，认识到其在提高患者生存率同时降低整体癌症治疗成本的潜力。例如在美国，医疗保险多癌症早期检测筛检覆盖法案等立法措施旨在扩大高风险族群获得 MCED 诊断的机会。同样，欧盟委员会的癌症计划优先考虑早期检测工作，并促进将液态切片的筛检纳入国家医疗保健计划。除了政策主导的倡议外，创业投资和私募股权投资涌入 MCED 领域也有助于加速技术进步和市场扩张。根据行业报告，过去五年来，开发 MCED 解决方案的精准肿瘤学新兴企业获得的资金大幅增长，数十亿美元的估值反映出投资者对该技术颠覆性潜力的信心。大型製药企业也正在与生技公司建立策略联盟，共同开发和商业化 MCED 产品，进一步推动研究和创新。然而，儘管存在这些积极趋势，监管标准化、检测可负担性和公众认知等挑战仍然是大规模应用的障碍。透过产业相关人员、政策制定者和医疗保健提供者之间的协作努力来克服这些障碍，对于确保 MCED 成为广泛且公平的早期癌症检测解决方案至关重要。

哪些市场驱动因素正在塑造 MCED 的未来？

全球多重癌症早期检测市场的成长受到多种因素的推动，包括技术的快速进步、精准医疗的日益普及以及全球癌症负担的不断增加。次世代定序(NGS) 和数位 PCR 的技术突破显着提高了 MCED 检测的敏感度和特异性，增强了早期癌症检测的可靠性。人工智慧和巨量资料分析与诊断工作流程的整合也简化了生物标记的发现，从而能够快速且准确地识别癌症特征。此外，个人化医疗（根据个人基因图谱客製化治疗和筛检）的趋势正在推动对先进 MCED 解决方案的需求。消费行为也是一个关键驱动因素，因为人们越来越意识到早期癌症检测的益处，患者正在寻求积极主动的医疗保健选择。直接面向消费者 (DTC) 的基因检测日益普及也促进了市场扩张，个人选择 MCED 检测作为其个人化健康监测策略的一部分。从最终用途的角度来看，医院、诊断实验室和研究机构是 MCED 技术的主要采用者，将这些检测纳入其常规癌症筛检计画。 MCED 的应用范围不断扩大，不仅限于肿瘤学，例如伴随诊断和治疗监测，这进一步拓宽了市场机会。此外，政府为降低癌症死亡率所做的努力正在推动支持采用 MCED 的政策框架。此外，由于医疗基础设施的改善和可支配收入的增加，新兴国家对先进诊断的需求激增。虽然市场预计会成长，但为了维持长期采用，必须解决监管的复杂性、围绕基因检测的伦理考量以及大规模检验研究的需求等挑战。儘管如此，随着技术创新不断突破极限，MCED 有望成为未来癌症预防和早期疗育的基石。

部分

类型（基因面板和 LDT、液态切片）、最终用途（医院、研究、其他）

受访公司范例

  • AnPac Bio-Medical Science Co., Ltd.
  • Becton, Dickinson and Company（BD）
  • Biocept, Inc.
  • Burning Rock Biotech Limited
  • Delfi Diagnostics, Inc.
  • Epigenomics AG
  • Exact Sciences Corporation
  • Freenome Holdings, Inc.
  • GRAIL, Inc.
  • Guardant Health, Inc.
  • Hologic, Inc.
  • Illumina, Inc.
  • Lucence Diagnostics Pte Ltd
  • Natera, Inc.
  • Oncimmune Holdings plc
  • Prenetics Global Limited
  • Qiagen NV
  • Roche Diagnostics
  • Siemens Healthineers
  • Thermo Fisher Scientific Inc.

人工智慧集成

全球产业分析师利用可操作的专家内容和人工智慧工具改变市场和竞争情报。

我们没有依赖典型的 LLM 或产业专用的SLM查询，而是建立了一个由来自世界各地的领域专家精心挑选的集中内容存储库，其中包括影片记录、博客、搜寻引擎研究以及大量的公司、产品、服务和市场数据。

关税影响係数

我们根据公司总部所在国家、製造地和进出口（成品和OEM）情况预测其竞争地位的变化。这种复杂多变的市场动态预计将对竞争对手产生影响，包括销货成本成本（COGS）上升、盈利下降、供应链重组等微观和宏观市场动态。

目录

第一章调查方法

第二章执行摘要

  • 市场概览
  • 主要企业
  • 市场趋势和驱动因素
  • 全球市场展望

第三章市场分析

  • 美国
  • 加拿大
  • 日本
  • 中国
  • 欧洲
  • 法国
  • 德国
  • 义大利
  • 英国
  • 西班牙
  • 俄罗斯
  • 其他欧洲国家
  • 亚太地区
  • 澳洲
  • 印度
  • 韩国
  • 其他亚太地区
  • 拉丁美洲
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他拉丁美洲
  • 中东
  • 伊朗
  • 以色列
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 其他中东地区
  • 非洲

第四章 竞赛

简介目录
Product Code: MCP32245

Global Multi Cancer Early Detection Market to Reach US$2.6 Billion by 2030

The global market for Multi Cancer Early Detection estimated at US$1.1 Billion in the year 2024, is expected to reach US$2.6 Billion by 2030, growing at a CAGR of 15.6% over the analysis period 2024-2030. Gene Panel & LDT, one of the segments analyzed in the report, is expected to record a 13.8% CAGR and reach US$1.4 Billion by the end of the analysis period. Growth in the Liquid Biopsy segment is estimated at 18.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$296.0 Million While China is Forecast to Grow at 20.4% CAGR

The Multi Cancer Early Detection market in the U.S. is estimated at US$296.0 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$556.8 Million by the year 2030 trailing a CAGR of 20.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 11.7% and 13.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 12.4% CAGR.

Global Multi-Cancer Early Detection Market - Key Trends & Drivers Summarized

How is Multi-Cancer Early Detection Reshaping Oncology Diagnostics?

The landscape of cancer detection is undergoing a seismic shift with the advent of Multi-Cancer Early Detection (MCED) technologies, a breakthrough that promises to revolutionize oncology diagnostics. Unlike conventional cancer screenings that target only a handful of malignancies-such as mammograms for breast cancer or colonoscopies for colorectal cancer-MCED tests utilize advanced genomic, epigenomic, and proteomic biomarkers to simultaneously detect multiple cancer types in a single assay. This is achieved through liquid biopsies, which analyze circulating tumor DNA (ctDNA), RNA signatures, and other molecular alterations in blood samples. As cancer remains a leading global cause of mortality, early detection is critical to improving survival rates. According to the World Health Organization (WHO), late-stage diagnoses account for a substantial proportion of cancer-related deaths, highlighting the urgent need for early, non-invasive, and comprehensive screening solutions. With artificial intelligence (AI) and machine learning (ML) algorithms enhancing biomarker identification, MCED tests are now more accurate, scalable, and accessible than ever before. Several biotech firms and research institutions have made significant strides in validating these tests through large-scale clinical trials, demonstrating their potential to identify cancers even before symptoms appear. The promise of reducing the burden of late-stage cancer diagnoses and improving patient outcomes has generated unprecedented excitement in the medical community, investors, and regulatory agencies alike.

What Role Do Liquid Biopsies and AI Play in Advancing MCED?

At the core of MCED technology lies the integration of liquid biopsies and artificial intelligence, two game-changing innovations that have significantly elevated the accuracy and efficiency of multi-cancer screening. Traditional tissue biopsies, while effective, are often invasive, expensive, and limited to specific cancer types. Liquid biopsies, in contrast, offer a minimally invasive alternative that can detect a broad spectrum of cancers by identifying tumor-derived genetic fragments in the bloodstream. This technique has been particularly beneficial in detecting hard-to-screen cancers, such as pancreatic, ovarian, and esophageal malignancies, which often remain undiagnosed until advanced stages. AI-driven pattern recognition further amplifies the power of MCED by rapidly analyzing vast datasets of genetic, proteomic, and metabolic markers to differentiate between benign and malignant signals. AI models trained on millions of patient samples can refine diagnostic accuracy, minimize false positives and negatives, and even predict the tissue of origin for detected cancers. The growing adoption of AI in MCED has also enabled continuous learning, where algorithms evolve to recognize emerging cancer subtypes and adapt to new molecular discoveries. Notably, companies such as GRAIL, Guardant Health, and Exact Sciences have spearheaded efforts in commercializing AI-powered liquid biopsy tests, with extensive clinical validation backing their efficacy. Furthermore, regulatory approvals, such as the breakthrough designation granted by the U.S. Food and Drug Administration (FDA) for leading MCED tests, signal a paradigm shift in how cancer screening is approached. As these technologies mature, their integration into routine health check-ups is expected to become a new standard in preventive medicine, transforming early detection into a cost-effective, life-saving strategy.

How Are Healthcare Policies and Market Investments Accelerating MCED Adoption?

Government policies, healthcare infrastructure, and investment trends play a pivotal role in shaping the trajectory of MCED market adoption. As healthcare systems worldwide grapple with the economic burden of late-stage cancer treatments, there is growing consensus on the cost-effectiveness of early detection strategies. Several national health agencies and insurance providers are exploring reimbursement models for MCED tests, acknowledging their potential to reduce overall cancer treatment costs while improving patient survival rates. In the United States, for instance, legislative efforts such as the Medicare Multi-Cancer Early Detection Screening Coverage Act aim to expand access to MCED diagnostics among high-risk populations. Similarly, the European Commission’s Cancer Plan has prioritized early detection initiatives, pushing for greater integration of liquid biopsy-based screenings into national healthcare programs. Beyond policy-driven efforts, the influx of venture capital and private equity investments in the MCED sector has been instrumental in accelerating technological advancements and market expansion. According to industry reports, funding for precision oncology startups developing MCED solutions has surged dramatically over the past five years, with multi-billion-dollar valuations reflecting investor confidence in the technology’s disruptive potential. Leading pharmaceutical giants have also entered strategic partnerships with biotech firms to co-develop and commercialize MCED products, further fueling research and innovation. However, despite these positive trends, challenges such as regulatory standardization, test affordability, and public awareness remain barriers to mass adoption. Addressing these hurdles through collaborative efforts between industry stakeholders, policymakers, and healthcare providers will be crucial in ensuring MCED becomes a widespread and equitable solution for early cancer detection.

What Are the Key Market Drivers Shaping the Future of MCED?

The growth in the global Multi-Cancer Early Detection market is driven by several factors, including rapid technological advancements, increasing adoption of precision medicine, and the rising burden of cancer worldwide. Technological breakthroughs in next-generation sequencing (NGS) and digital PCR have significantly enhanced the sensitivity and specificity of MCED tests, making them more reliable for early-stage cancer detection. The integration of AI and big data analytics into diagnostic workflows has also streamlined biomarker discovery, allowing for faster and more accurate identification of cancer signatures. Additionally, the shift toward personalized medicine, where treatments and screenings are tailored to individual genetic profiles, has fueled demand for advanced MCED solutions. Consumer behavior is another critical driver, as awareness about the benefits of early cancer detection grows and patients increasingly seek proactive healthcare options. The rising prevalence of direct-to-consumer (DTC) genetic testing has also contributed to market expansion, with individuals opting for MCED tests as part of their personalized health monitoring strategies. From an end-use perspective, hospitals, diagnostic laboratories, and research institutions are among the key adopters of MCED technologies, integrating these tests into routine cancer screening programs. The expanding applications of MCED beyond oncology-such as in companion diagnostics and treatment monitoring-have further broadened market opportunities. Additionally, government initiatives aimed at reducing cancer mortality rates have driven policy frameworks that support MCED adoption. Emerging economies are also witnessing a surge in demand for advanced diagnostics, fueled by improving healthcare infrastructure and increasing disposable incomes. While market growth is promising, challenges such as regulatory complexities, ethical considerations surrounding genetic testing, and the need for large-scale validation studies must be addressed to sustain long-term adoption. Nevertheless, as innovation continues to push boundaries, MCED is poised to become a cornerstone in the future of cancer prevention and early intervention.

SCOPE OF STUDY:

The report analyzes the Multi Cancer Early Detection market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Gene Panel & LDT, Liquid Biopsy); End-Use (Hospitals End-Use, Diagnostic Laboratories End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 48 Featured) -

  • AnPac Bio-Medical Science Co., Ltd.
  • Becton, Dickinson and Company (BD)
  • Biocept, Inc.
  • Burning Rock Biotech Limited
  • Delfi Diagnostics, Inc.
  • Epigenomics AG
  • Exact Sciences Corporation
  • Freenome Holdings, Inc.
  • GRAIL, Inc.
  • Guardant Health, Inc.
  • Hologic, Inc.
  • Illumina, Inc.
  • Lucence Diagnostics Pte Ltd
  • Natera, Inc.
  • Oncimmune Holdings plc
  • Prenetics Global Limited
  • Qiagen N.V.
  • Roche Diagnostics
  • Siemens Healthineers
  • Thermo Fisher Scientific Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Multi Cancer Early Detection - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Global Cancer Prevalence Drives Accelerated Demand for Early Detection Technologies
    • Growing Investment in Liquid Biopsy and Non-invasive Testing Expands Market Opportunities for Multi Cancer Early Detection
    • Advances in Molecular Diagnostics and AI-driven Algorithms Propel Growth in Multi Cancer Early Detection Solutions
    • Rising Demand for Personalized Healthcare Solutions Strengthens the Business Case for Multi Cancer Early Detection
    • Surge in Preventive Healthcare Initiatives and Early Screening Programs Stimulates Adoption of Multi Cancer Detection Technologies
    • Regulatory Support and Approvals for Multi Cancer Early Detection Tests Expand Market Reach
    • Increasing Consumer Awareness of Cancer Risk Factors and Early Detection Benefits Accelerates Market Adoption
    • Technological Advancements in Biomarker Discovery Enhance the Sensitivity and Accuracy of Multi Cancer Early Detection Tests
    • Rising Focus on Minimally Invasive Diagnostic Methods Drives Demand for Multi Cancer Detection Solutions
    • The Expansion of Cancer Screening Guidelines and Reimbursement Policies Generates Growth in the Multi Cancer Early Detection Market
    • Growth in Telemedicine and Remote Healthcare Services Expands the Reach of Multi Cancer Detection Technologies in Rural Areas
    • The Rise in Targeted Cancer Therapies and Precision Medicine Strengthens Demand for Early Detection and Diagnosis Solutions
    • Increased Focus on Early Disease Intervention and Cost-effective Cancer Management Drives Adoption of Multi Cancer Early Detection
    • Surge in Government Funding for Cancer Research and Early Screening Drives Technological Advancements in Multi Cancer Detection
    • The Growing Use of Wearable Devices and Health Apps for Cancer Monitoring Expands Opportunities for Integration with Early Detection Solutions
    • The Emergence of Multi-omics Approaches in Cancer Detection Expands Market Potential for Next-generation Diagnostic Tools
    • Rising Global Cancer Awareness and Screening Initiatives in Developing Economies Boost Demand for Multi Cancer Detection Solutions
    • Strategic Partnerships Between Biotech Firms and Healthcare Providers Propel Market Growth and Innovation in Early Detection Technologies
    • The Increasing Incidence of Cancer in Younger Populations Expands the Addressable Market for Early Detection Tools
    • Growing Interest in Cancer Prevention and Early Detection for High-risk Populations Stimulates Demand for Multi Cancer Screening Tests
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Multi Cancer Early Detection Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Multi Cancer Early Detection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Multi Cancer Early Detection by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Gene Panel & LDT by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Gene Panel & LDT by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Liquid Biopsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Liquid Biopsy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Diagnostic Laboratories End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Diagnostic Laboratories End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Multi Cancer Early Detection Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 14: USA Recent Past, Current & Future Analysis for Multi Cancer Early Detection by Type - Gene Panel & LDT and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 15: USA 6-Year Perspective for Multi Cancer Early Detection by Type - Percentage Breakdown of Value Sales for Gene Panel & LDT and Liquid Biopsy for the Years 2025 & 2030
    • TABLE 16: USA Recent Past, Current & Future Analysis for Multi Cancer Early Detection by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 17: USA 6-Year Perspective for Multi Cancer Early Detection by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2025 & 2030
  • CANADA
    • TABLE 18: Canada Recent Past, Current & Future Analysis for Multi Cancer Early Detection by Type - Gene Panel & LDT and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 19: Canada 6-Year Perspective for Multi Cancer Early Detection by Type - Percentage Breakdown of Value Sales for Gene Panel & LDT and Liquid Biopsy for the Years 2025 & 2030
    • TABLE 20: Canada Recent Past, Current & Future Analysis for Multi Cancer Early Detection by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 21: Canada 6-Year Perspective for Multi Cancer Early Detection by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2025 & 2030
  • JAPAN
    • Multi Cancer Early Detection Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 22: Japan Recent Past, Current & Future Analysis for Multi Cancer Early Detection by Type - Gene Panel & LDT and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 23: Japan 6-Year Perspective for Multi Cancer Early Detection by Type - Percentage Breakdown of Value Sales for Gene Panel & LDT and Liquid Biopsy for the Years 2025 & 2030
    • TABLE 24: Japan Recent Past, Current & Future Analysis for Multi Cancer Early Detection by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 25: Japan 6-Year Perspective for Multi Cancer Early Detection by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2025 & 2030
  • CHINA
    • Multi Cancer Early Detection Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 26: China Recent Past, Current & Future Analysis for Multi Cancer Early Detection by Type - Gene Panel & LDT and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: China 6-Year Perspective for Multi Cancer Early Detection by Type - Percentage Breakdown of Value Sales for Gene Panel & LDT and Liquid Biopsy for the Years 2025 & 2030
    • TABLE 28: China Recent Past, Current & Future Analysis for Multi Cancer Early Detection by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 29: China 6-Year Perspective for Multi Cancer Early Detection by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2025 & 2030
  • EUROPE
    • Multi Cancer Early Detection Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 30: Europe Recent Past, Current & Future Analysis for Multi Cancer Early Detection by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 31: Europe 6-Year Perspective for Multi Cancer Early Detection by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 32: Europe Recent Past, Current & Future Analysis for Multi Cancer Early Detection by Type - Gene Panel & LDT and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Europe 6-Year Perspective for Multi Cancer Early Detection by Type - Percentage Breakdown of Value Sales for Gene Panel & LDT and Liquid Biopsy for the Years 2025 & 2030
    • TABLE 34: Europe Recent Past, Current & Future Analysis for Multi Cancer Early Detection by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 35: Europe 6-Year Perspective for Multi Cancer Early Detection by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2025 & 2030
  • FRANCE
    • Multi Cancer Early Detection Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 36: France Recent Past, Current & Future Analysis for Multi Cancer Early Detection by Type - Gene Panel & LDT and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 37: France 6-Year Perspective for Multi Cancer Early Detection by Type - Percentage Breakdown of Value Sales for Gene Panel & LDT and Liquid Biopsy for the Years 2025 & 2030
    • TABLE 38: France Recent Past, Current & Future Analysis for Multi Cancer Early Detection by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: France 6-Year Perspective for Multi Cancer Early Detection by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2025 & 2030
  • GERMANY
    • Multi Cancer Early Detection Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 40: Germany Recent Past, Current & Future Analysis for Multi Cancer Early Detection by Type - Gene Panel & LDT and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 41: Germany 6-Year Perspective for Multi Cancer Early Detection by Type - Percentage Breakdown of Value Sales for Gene Panel & LDT and Liquid Biopsy for the Years 2025 & 2030
    • TABLE 42: Germany Recent Past, Current & Future Analysis for Multi Cancer Early Detection by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 43: Germany 6-Year Perspective for Multi Cancer Early Detection by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2025 & 2030
  • ITALY
    • TABLE 44: Italy Recent Past, Current & Future Analysis for Multi Cancer Early Detection by Type - Gene Panel & LDT and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Italy 6-Year Perspective for Multi Cancer Early Detection by Type - Percentage Breakdown of Value Sales for Gene Panel & LDT and Liquid Biopsy for the Years 2025 & 2030
    • TABLE 46: Italy Recent Past, Current & Future Analysis for Multi Cancer Early Detection by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 47: Italy 6-Year Perspective for Multi Cancer Early Detection by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2025 & 2030
  • UNITED KINGDOM
    • Multi Cancer Early Detection Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 48: UK Recent Past, Current & Future Analysis for Multi Cancer Early Detection by Type - Gene Panel & LDT and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 49: UK 6-Year Perspective for Multi Cancer Early Detection by Type - Percentage Breakdown of Value Sales for Gene Panel & LDT and Liquid Biopsy for the Years 2025 & 2030
    • TABLE 50: UK Recent Past, Current & Future Analysis for Multi Cancer Early Detection by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: UK 6-Year Perspective for Multi Cancer Early Detection by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2025 & 2030
  • SPAIN
    • TABLE 52: Spain Recent Past, Current & Future Analysis for Multi Cancer Early Detection by Type - Gene Panel & LDT and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 53: Spain 6-Year Perspective for Multi Cancer Early Detection by Type - Percentage Breakdown of Value Sales for Gene Panel & LDT and Liquid Biopsy for the Years 2025 & 2030
    • TABLE 54: Spain Recent Past, Current & Future Analysis for Multi Cancer Early Detection by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 55: Spain 6-Year Perspective for Multi Cancer Early Detection by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2025 & 2030
  • RUSSIA
    • TABLE 56: Russia Recent Past, Current & Future Analysis for Multi Cancer Early Detection by Type - Gene Panel & LDT and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Russia 6-Year Perspective for Multi Cancer Early Detection by Type - Percentage Breakdown of Value Sales for Gene Panel & LDT and Liquid Biopsy for the Years 2025 & 2030
    • TABLE 58: Russia Recent Past, Current & Future Analysis for Multi Cancer Early Detection by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 59: Russia 6-Year Perspective for Multi Cancer Early Detection by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 60: Rest of Europe Recent Past, Current & Future Analysis for Multi Cancer Early Detection by Type - Gene Panel & LDT and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 61: Rest of Europe 6-Year Perspective for Multi Cancer Early Detection by Type - Percentage Breakdown of Value Sales for Gene Panel & LDT and Liquid Biopsy for the Years 2025 & 2030
    • TABLE 62: Rest of Europe Recent Past, Current & Future Analysis for Multi Cancer Early Detection by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Rest of Europe 6-Year Perspective for Multi Cancer Early Detection by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Multi Cancer Early Detection Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 64: Asia-Pacific Recent Past, Current & Future Analysis for Multi Cancer Early Detection by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 65: Asia-Pacific 6-Year Perspective for Multi Cancer Early Detection by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2025 & 2030
    • TABLE 66: Asia-Pacific Recent Past, Current & Future Analysis for Multi Cancer Early Detection by Type - Gene Panel & LDT and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 67: Asia-Pacific 6-Year Perspective for Multi Cancer Early Detection by Type - Percentage Breakdown of Value Sales for Gene Panel & LDT and Liquid Biopsy for the Years 2025 & 2030
    • TABLE 68: Asia-Pacific Recent Past, Current & Future Analysis for Multi Cancer Early Detection by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Asia-Pacific 6-Year Perspective for Multi Cancer Early Detection by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2025 & 2030
  • AUSTRALIA
    • Multi Cancer Early Detection Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 70: Australia Recent Past, Current & Future Analysis for Multi Cancer Early Detection by Type - Gene Panel & LDT and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 71: Australia 6-Year Perspective for Multi Cancer Early Detection by Type - Percentage Breakdown of Value Sales for Gene Panel & LDT and Liquid Biopsy for the Years 2025 & 2030
    • TABLE 72: Australia Recent Past, Current & Future Analysis for Multi Cancer Early Detection by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 73: Australia 6-Year Perspective for Multi Cancer Early Detection by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2025 & 2030
  • INDIA
    • Multi Cancer Early Detection Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 74: India Recent Past, Current & Future Analysis for Multi Cancer Early Detection by Type - Gene Panel & LDT and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: India 6-Year Perspective for Multi Cancer Early Detection by Type - Percentage Breakdown of Value Sales for Gene Panel & LDT and Liquid Biopsy for the Years 2025 & 2030
    • TABLE 76: India Recent Past, Current & Future Analysis for Multi Cancer Early Detection by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 77: India 6-Year Perspective for Multi Cancer Early Detection by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2025 & 2030
  • SOUTH KOREA
    • TABLE 78: South Korea Recent Past, Current & Future Analysis for Multi Cancer Early Detection by Type - Gene Panel & LDT and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 79: South Korea 6-Year Perspective for Multi Cancer Early Detection by Type - Percentage Breakdown of Value Sales for Gene Panel & LDT and Liquid Biopsy for the Years 2025 & 2030
    • TABLE 80: South Korea Recent Past, Current & Future Analysis for Multi Cancer Early Detection by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: South Korea 6-Year Perspective for Multi Cancer Early Detection by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 82: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Multi Cancer Early Detection by Type - Gene Panel & LDT and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 83: Rest of Asia-Pacific 6-Year Perspective for Multi Cancer Early Detection by Type - Percentage Breakdown of Value Sales for Gene Panel & LDT and Liquid Biopsy for the Years 2025 & 2030
    • TABLE 84: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Multi Cancer Early Detection by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 85: Rest of Asia-Pacific 6-Year Perspective for Multi Cancer Early Detection by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2025 & 2030
  • LATIN AMERICA
    • Multi Cancer Early Detection Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 86: Latin America Recent Past, Current & Future Analysis for Multi Cancer Early Detection by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 87: Latin America 6-Year Perspective for Multi Cancer Early Detection by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2025 & 2030
    • TABLE 88: Latin America Recent Past, Current & Future Analysis for Multi Cancer Early Detection by Type - Gene Panel & LDT and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Latin America 6-Year Perspective for Multi Cancer Early Detection by Type - Percentage Breakdown of Value Sales for Gene Panel & LDT and Liquid Biopsy for the Years 2025 & 2030
    • TABLE 90: Latin America Recent Past, Current & Future Analysis for Multi Cancer Early Detection by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Latin America 6-Year Perspective for Multi Cancer Early Detection by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2025 & 2030
  • ARGENTINA
    • TABLE 92: Argentina Recent Past, Current & Future Analysis for Multi Cancer Early Detection by Type - Gene Panel & LDT and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Argentina 6-Year Perspective for Multi Cancer Early Detection by Type - Percentage Breakdown of Value Sales for Gene Panel & LDT and Liquid Biopsy for the Years 2025 & 2030
    • TABLE 94: Argentina Recent Past, Current & Future Analysis for Multi Cancer Early Detection by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 95: Argentina 6-Year Perspective for Multi Cancer Early Detection by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2025 & 2030
  • BRAZIL
    • TABLE 96: Brazil Recent Past, Current & Future Analysis for Multi Cancer Early Detection by Type - Gene Panel & LDT and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 97: Brazil 6-Year Perspective for Multi Cancer Early Detection by Type - Percentage Breakdown of Value Sales for Gene Panel & LDT and Liquid Biopsy for the Years 2025 & 2030
    • TABLE 98: Brazil Recent Past, Current & Future Analysis for Multi Cancer Early Detection by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Brazil 6-Year Perspective for Multi Cancer Early Detection by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2025 & 2030
  • MEXICO
    • TABLE 100: Mexico Recent Past, Current & Future Analysis for Multi Cancer Early Detection by Type - Gene Panel & LDT and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 101: Mexico 6-Year Perspective for Multi Cancer Early Detection by Type - Percentage Breakdown of Value Sales for Gene Panel & LDT and Liquid Biopsy for the Years 2025 & 2030
    • TABLE 102: Mexico Recent Past, Current & Future Analysis for Multi Cancer Early Detection by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 103: Mexico 6-Year Perspective for Multi Cancer Early Detection by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 104: Rest of Latin America Recent Past, Current & Future Analysis for Multi Cancer Early Detection by Type - Gene Panel & LDT and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Rest of Latin America 6-Year Perspective for Multi Cancer Early Detection by Type - Percentage Breakdown of Value Sales for Gene Panel & LDT and Liquid Biopsy for the Years 2025 & 2030
    • TABLE 106: Rest of Latin America Recent Past, Current & Future Analysis for Multi Cancer Early Detection by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 107: Rest of Latin America 6-Year Perspective for Multi Cancer Early Detection by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2025 & 2030
  • MIDDLE EAST
    • Multi Cancer Early Detection Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 108: Middle East Recent Past, Current & Future Analysis for Multi Cancer Early Detection by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 109: Middle East 6-Year Perspective for Multi Cancer Early Detection by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2025 & 2030
    • TABLE 110: Middle East Recent Past, Current & Future Analysis for Multi Cancer Early Detection by Type - Gene Panel & LDT and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Middle East 6-Year Perspective for Multi Cancer Early Detection by Type - Percentage Breakdown of Value Sales for Gene Panel & LDT and Liquid Biopsy for the Years 2025 & 2030
    • TABLE 112: Middle East Recent Past, Current & Future Analysis for Multi Cancer Early Detection by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 113: Middle East 6-Year Perspective for Multi Cancer Early Detection by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2025 & 2030
  • IRAN
    • TABLE 114: Iran Recent Past, Current & Future Analysis for Multi Cancer Early Detection by Type - Gene Panel & LDT and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 115: Iran 6-Year Perspective for Multi Cancer Early Detection by Type - Percentage Breakdown of Value Sales for Gene Panel & LDT and Liquid Biopsy for the Years 2025 & 2030
    • TABLE 116: Iran Recent Past, Current & Future Analysis for Multi Cancer Early Detection by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Iran 6-Year Perspective for Multi Cancer Early Detection by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2025 & 2030
  • ISRAEL
    • TABLE 118: Israel Recent Past, Current & Future Analysis for Multi Cancer Early Detection by Type - Gene Panel & LDT and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 119: Israel 6-Year Perspective for Multi Cancer Early Detection by Type - Percentage Breakdown of Value Sales for Gene Panel & LDT and Liquid Biopsy for the Years 2025 & 2030
    • TABLE 120: Israel Recent Past, Current & Future Analysis for Multi Cancer Early Detection by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 121: Israel 6-Year Perspective for Multi Cancer Early Detection by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2025 & 2030
  • SAUDI ARABIA
    • TABLE 122: Saudi Arabia Recent Past, Current & Future Analysis for Multi Cancer Early Detection by Type - Gene Panel & LDT and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Saudi Arabia 6-Year Perspective for Multi Cancer Early Detection by Type - Percentage Breakdown of Value Sales for Gene Panel & LDT and Liquid Biopsy for the Years 2025 & 2030
    • TABLE 124: Saudi Arabia Recent Past, Current & Future Analysis for Multi Cancer Early Detection by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 125: Saudi Arabia 6-Year Perspective for Multi Cancer Early Detection by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 126: UAE Recent Past, Current & Future Analysis for Multi Cancer Early Detection by Type - Gene Panel & LDT and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 127: UAE 6-Year Perspective for Multi Cancer Early Detection by Type - Percentage Breakdown of Value Sales for Gene Panel & LDT and Liquid Biopsy for the Years 2025 & 2030
    • TABLE 128: UAE Recent Past, Current & Future Analysis for Multi Cancer Early Detection by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: UAE 6-Year Perspective for Multi Cancer Early Detection by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 130: Rest of Middle East Recent Past, Current & Future Analysis for Multi Cancer Early Detection by Type - Gene Panel & LDT and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 131: Rest of Middle East 6-Year Perspective for Multi Cancer Early Detection by Type - Percentage Breakdown of Value Sales for Gene Panel & LDT and Liquid Biopsy for the Years 2025 & 2030
    • TABLE 132: Rest of Middle East Recent Past, Current & Future Analysis for Multi Cancer Early Detection by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 133: Rest of Middle East 6-Year Perspective for Multi Cancer Early Detection by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2025 & 2030
  • AFRICA
    • Multi Cancer Early Detection Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 134: Africa Recent Past, Current & Future Analysis for Multi Cancer Early Detection by Type - Gene Panel & LDT and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Africa 6-Year Perspective for Multi Cancer Early Detection by Type - Percentage Breakdown of Value Sales for Gene Panel & LDT and Liquid Biopsy for the Years 2025 & 2030
    • TABLE 136: Africa Recent Past, Current & Future Analysis for Multi Cancer Early Detection by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 137: Africa 6-Year Perspective for Multi Cancer Early Detection by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2025 & 2030

IV. COMPETITION